Key clinical point: An artificial intelligence–derived algorithm predicted success for three non–small cell lung cancer therapies.
Major finding: The prediction models for nivolumab, docetaxel, and gefitinib yielded area under the curve results of 0.77, 0.67, and 0.82, respectively.
Study details: A retrospective analysis of data from clinical trials of 188 patients with non–small cell lung cancer.
Disclosures: The study was supported by Bristol-Myers Squibb, the National Institutes of Health, Fondation Philanthropia, and Fondation Nuovo-Soldati. The authors disclosed relationships, including employment, with Bristol-Myers Squibb. They also disclosed relationships with Roche, Novartis, Merck, and Boehringer Ingelheim.
Dercle L et al. Clin Cancer Res. 2020 Mar 20. doi: 10.1158/1078-0432.CCR-19-2942.